Literature DB >> 25262116

Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.

Elizabeth S DeWitt1, John K Triedman1, Frank Cecchin1, Doug Y Mah1, Dominic J Abrams1, Edward P Walsh1, Kimberlee Gauvreau1, Mark E Alexander2.   

Abstract

BACKGROUND: Implantable cardioverter defibrillators (ICDs) used to prevent sudden cardiac arrest in children not only provide appropriate therapy in 25% of patients but also result in a significant incidence of inappropriate shocks and other device complications. ICDs placed for secondary prevention have higher rates of appropriate therapy than those placed for primary prevention. Pediatric patients with primary prevention ICDs were studied to determine time-dependent incidence of appropriate use and adverse events. METHODS AND
RESULTS: A total of 140 patients aged <21 years (median age, 15 years) at first ICD implantation at Boston Children's Hospital (2000-2009) in whom devices were placed for primary prevention were retrospectively identified. Demographics and times to first appropriate shock; adverse events (including inappropriate shock, lead failure, reintervention, and complication); generator replacement and follow-up were noted. During mean follow-up of 4 years, appropriate shock occurred in 19% patients and first adverse event (excluding death/transplant) occurred in 36%. Risk of death or transplant was ≈1% per year and was not related to receiving appropriate therapy. Conditional survival analysis showed rates of appropriate therapy and adverse events decrease soon after implantation, but adverse events are more frequent than appropriate therapy throughout follow-up.
CONCLUSIONS: Primary prevention ICDs were associated with appropriate therapy in 19% and adverse event in 36% in this cohort. The incidence of both first appropriate therapy and device-related adverse events decreased during longer periods of follow-up after implantation. This suggests that indications for continued device therapy in pediatric primary prevention ICD patients might be reconsidered after a period of nonuse.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  arrhythmias, cardiac; death, sudden, cardiac; defibrillators, implantable; pediatrics

Mesh:

Year:  2014        PMID: 25262116     DOI: 10.1161/CIRCEP.114.001569

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  8 in total

1.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

2.  Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca2+/Calmodulin-Dependent Kinase II.

Authors:  Vassilios J Bezzerides; Ana Caballero; Suya Wang; Yulan Ai; Robyn J Hylind; Fujian Lu; Danielle A Heims-Waldron; Kristina D Chambers; Donghui Zhang; Dominic J Abrams; William T Pu
Journal:  Circulation       Date:  2019-06-03       Impact factor: 29.690

3.  Exercise Recommendations in Pediatric HCM: Variation and Influence of Provider Characteristics.

Authors:  Robert D Whitehill; Seshadri Balaji; Michael Kelleman; Stephanie F Chandler; Dominic J Abrams; Chad Mao; Peter Fischbach; Robert Campbell
Journal:  Pediatr Cardiol       Date:  2021-08-18       Impact factor: 1.655

Review 4.  Sudden Cardiac Death in the Young.

Authors:  Michael Ackerman; Dianne L Atkins; John K Triedman
Journal:  Circulation       Date:  2016-03-08       Impact factor: 29.690

5.  Prevention of Sudden Cardiac Death in Children and Young Adults.

Authors:  Aapo L Aro; Sumeet S Chugh
Journal:  Prog Pediatr Cardiol       Date:  2017-03-21

6.  Outcomes of Pediatric Patients With Defibrillators Following Initial Presentation With Sudden Cardiac Arrest.

Authors:  Jeffrey A Robinson; Martin J LaPage; Joseph Atallah; Gregory Webster; Christina Y Miyake; Christopher Ratnasamy; Nicholas J Ollberding; Shaun Mohan; Nicholas H Von Bergen; Christopher L Johnsrude; Jason M Garnreiter; David S Spar; Richard J Czosek
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-01-05

7.  ICD Outcome in Pediatric Cardiomyopathies.

Authors:  Massimo Stefano Silvetti; Ilaria Tamburri; Marta Campisi; Fabio Anselmo Saputo; Ilaria Cazzoli; Nicoletta Cantarutti; Marianna Cicenia; Rachele Adorisio; Anwar Baban; Lucilla Ravà; Fabrizio Drago
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-20

8.  A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy.

Authors:  Anastasia Miron; Myriam Lafreniere-Roula; Chun-Po Steve Fan; Katey R Armstrong; Andreea Dragulescu; Tanya Papaz; Cedric Manlhiot; Beth Kaufman; Ryan J Butts; Letizia Gardin; Elizabeth A Stephenson; Taylor S Howard; Pete F Aziz; Seshadri Balaji; Virginie Beauséjour Ladouceur; Lee N Benson; Steven D Colan; Justin Godown; Heather T Henderson; Jodie Ingles; Aamir Jeewa; John L Jefferies; Ashwin K Lal; Jacob Mathew; Emilie Jean-St-Michel; Michelle Michels; Stephanie J Nakano; Iacopo Olivotto; John J Parent; Alexandre C Pereira; Christopher Semsarian; Robert D Whitehill; Samuel G Wittekind; Mark W Russell; Jennifer Conway; Marc E Richmond; Chet Villa; Robert G Weintraub; Joseph W Rossano; Paul F Kantor; Carolyn Y Ho; Seema Mital
Journal:  Circulation       Date:  2020-05-18       Impact factor: 29.690

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.